Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 106Neoplasm Metastasis 9Ovarian Neoplasms 3Carcinoma, Intraductal, Noninfiltrating 3Breast Neoplasms, Male 3Prostatic Neoplasms 2Obesity 2Carcinoma, Non-Small-Cell Lung 2Breast Diseases 2Breast Carcinoma In Situ 2Breast Cancer Metastatic 2Arthralgia 2Triple Negative Breast Neoplasms 1Sexuality 1Sexual Dysfunctions, Psychological 1Recurrence 1Primary Breast Cancer ER+ve 1Premenopausal Breast Cancer 1Patient Acceptance of Health Care 1Pancreatic Neoplasms 1Pain 1Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1Multiple Endocrine Neoplasia Type 1 1Metastatic Beast Cancer 1Locoregional Recurrence 1Hyperglycemia 1Human Epidermal Growth Factor 2 Negative Carcinoma of Breast 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1Hormone Receptor Positive Malignant Neoplasm of Breast 1HR Positive HER2 Negative Advanced Breast Cancer 1

Interventions

trastuzumab biosimilar HLX02 1exemestane 1X-Rays 1Trastuzumab 1Taxes 1TVB-2640 1Specimen Handling 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Fulvestrant 1Disulfides 1CT-P6 1Biopsy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Breast Carcinoma × exemestane × Clear all
NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡